X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Napo Pharmaceuticals
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2021
Details:
Mytesi, only oral plant-based prescription medicine approved under FDA Botanical Guidance, is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HT-003
Therapeutic Area: Gastroenterology Product Name: HT-003
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Isoprene Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
News Type
